The Conversation (0)
Ceapro (TSX-V:CZO) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the quarter ended March 31, 2018. As quoted in the press release: “The exciting evolution of Ceapro has continued in 2018. While we continue to leverage on our de-risked …
Ceapro (TSX-V:CZO) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the quarter ended March 31, 2018.
As quoted in the press release:
“The exciting evolution of Ceapro has continued in 2018. While we continue to leverage on our de-risked base business model in cosmeceuticals through a distribution network, we are pursuing the diversification of this model by getting closer to the customer through the offering of the JuventeDC line of high-end value cosmeceuticals products, and by further investing in clinically validating new product applications for our value drivers, avenanthramides and beta glucan. We believe this is an important step that will enable the expansion of Ceapro to its next phase of growth into the profitable nutraceutical sector before year end,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro. “We remain focused on advancing our development programs with our two value drivers and believe that positive results from the nearly completed bioavailability study with the new chemical entity beta glucan CoQ10, as well as from the bioefficacy study of avenanthramides in exercise induced inflammation would position Ceapro to accelerate this transition as well as partnering discussions with key players in the nutraceutical sector.”